Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens

Berthony Deslouches, Jonathan D. Steckbeck, Jodi K. Craigo, Yohei Doi, Jane L. Burns, Ronald C. Montelaro

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

Original languageEnglish
Pages (from-to)1329-1333
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume59
Issue number2
DOIs
Publication statusPublished - 01-02-2015

Fingerprint

Antimicrobial Cationic Peptides
Multiple Drug Resistance
Anti-Bacterial Agents
Colistin
Aptitude
Bacteria
Peptides

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Deslouches, Berthony ; Steckbeck, Jonathan D. ; Craigo, Jodi K. ; Doi, Yohei ; Burns, Jane L. ; Montelaro, Ronald C. / Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. In: Antimicrobial agents and chemotherapy. 2015 ; Vol. 59, No. 2. pp. 1329-1333.
@article{5d7f5b873523434389feee0e048e5ee8,
title = "Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens",
abstract = "Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.",
author = "Berthony Deslouches and Steckbeck, {Jonathan D.} and Craigo, {Jodi K.} and Yohei Doi and Burns, {Jane L.} and Montelaro, {Ronald C.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1128/AAC.03937-14",
language = "English",
volume = "59",
pages = "1329--1333",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. / Deslouches, Berthony; Steckbeck, Jonathan D.; Craigo, Jodi K.; Doi, Yohei; Burns, Jane L.; Montelaro, Ronald C.

In: Antimicrobial agents and chemotherapy, Vol. 59, No. 2, 01.02.2015, p. 1329-1333.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens

AU - Deslouches, Berthony

AU - Steckbeck, Jonathan D.

AU - Craigo, Jodi K.

AU - Doi, Yohei

AU - Burns, Jane L.

AU - Montelaro, Ronald C.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

AB - Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=84921894902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921894902&partnerID=8YFLogxK

U2 - 10.1128/AAC.03937-14

DO - 10.1128/AAC.03937-14

M3 - Article

VL - 59

SP - 1329

EP - 1333

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -